English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Drug Names, Population Level Surveillance and the FDA's Adverse EventReporting System: An Exploratory Data Survey of Drug Name Incidence andPrevalence, 2004-2012Q2 Purpose: To count and monitor the drug names reportedin the publicly available version of the Federal Adverse Event Reporting System(FAERS) from 2004 to 2012Q2 in a maximized sensitivity relational model.Methods: Data mining and data modeling was conducted and event based summarystatistics with plots were created from over nine continuous years ofcontinuous FAERS data. Results: This FAERS model contains 344,452 individualdrug names and 432,541,994 count references which occurred across 4,148,761human subjects in the 34 quarter study period. Plots for the top 100 scoringdrug name references are reported by year and quarter; the top 100 drug namescontain 143,384,240 references or 33% of all drug name references over 34quarters of continuous FAERS data. Conclusions: While FAERS contains many drugsand adverse event reports, its data pertains to very few of them. Drug nameincidence lends timely and effective surveillance of large populations ofAverse Event Reports and does not require the cause of the AE, nor its validityto be known to detect a mass poisoning.

An Exploratory Data Survey of Drug Name Incidence and Prevalence From the FDA's Adverse Event Reporting System, 2004 to 2012Q2